* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download renin-angiotensin system gene polymorphisms and the risk of stroke
History of genetic engineering wikipedia , lookup
Vectors in gene therapy wikipedia , lookup
Genetic engineering wikipedia , lookup
Neuronal ceroid lipofuscinosis wikipedia , lookup
Therapeutic gene modulation wikipedia , lookup
Epigenetics of neurodegenerative diseases wikipedia , lookup
Gene desert wikipedia , lookup
Gene expression profiling wikipedia , lookup
Gene expression programming wikipedia , lookup
Gene therapy of the human retina wikipedia , lookup
Site-specific recombinase technology wikipedia , lookup
Gene nomenclature wikipedia , lookup
Genome (book) wikipedia , lookup
Public health genomics wikipedia , lookup
Polymorphism (biology) wikipedia , lookup
Gene therapy wikipedia , lookup
Artificial gene synthesis wikipedia , lookup
Epigenetics of diabetes Type 2 wikipedia , lookup
Designer baby wikipedia , lookup
Nutriepigenomics wikipedia , lookup
Microevolution wikipedia , lookup
1195, oral or poster, cat: 45 RENIN-ANGIOTENSIN SYSTEM GENE POLYMORPHISMS AND THE RISK OF STROKE IN PATIENTS WITH ATRIAL FIBRILLATION: A PROSPECTIVE OBSERVATION STUDY C.T. Tsai, J.L. Lin, J.J. Hwang, L.P. Lai National Taiwan University Hospital, Taipei, Taiwan Little evidence is available for the impact of genetic polymorphisms on the risk of stroke in patients with AF. Angiotensin II plays a pathophysiological role in prothrombotic endocardial remodeling. We planned to investigate the effect of polymorphisms of renin-angiotensin system genes on the incidence of stroke in a prospective cohort of patients with atrial fibrillation (AF). We assessed 311 AF patients and longitudinally followed up for 7.3+/-1.8 years. +/-G-217A, G-152A, A-20C, G-6A, M235T and T174M polymorphisms of angiotensinogen (AGT) gene, I/D polymorphism of ACE gene, and A1166C polymorphism of AT1R were genotyped. Incident physician-diagnosed ischemic stroke was the outcome measure. At the end of follow-up, thirty-one patients developed stroke. G-6A polymorphism of AGT gene was associated with the risk of stroke. Patients carrying G-6 allele were more likely to develop stroke than non-carriers (log-rank P=0.012). In Cox analysis, subjects carrying G-6 had increased risk of stroke (HR 2.74, 95% CI 1.23-6.11; P=0.014) after adjustment for non-genetic covariates. In AGT gene haplotype analysis, haplotypes consisting of -217G/-6G were associated with risk of AF (P=0.011). G-217/G-6 haplotype carriers were more likely to develop stroke than non-carriers (log-rank p=0.003). For pharmacogenetic analysis, the risk of stroke in subjects carrying G-6 was comparable to non-carriers, if they took ACEI or ARB during follow-up. In conclusions, AGT gene polymorphisms may be considered a genetic marker predisposing to an increase in risk of stroke in subjects with AF. From a pharmacogenetic view, ACEI or ARB may prevent stroke in patients with high risk AGT gene variants.